Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH

Stephen A. Harrison, Patrick R. Mayo, Todd M. Hobbs, Carlos Canizares, Erin P. Foster, Caroline Zhao, Daren R. Ure, Daniel J. Trepanier, Jill A. Greytok, Robert T. Foster – 21 October 2022 – Rencofilstat (RCF) demonstrated antifibrotic effects in preclinical models and was safe and well tolerated in Phase 1 studies. The aim of this Phase 2a study was safety, tolerability, pharmacokinetics, and exploration of efficacy biomarkers in subjects with nonalcoholic steatohepatitis (NASH).

Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study

Diana Buzova, Maria Rita Braghini, Salvatore Daniele Bianco, Oriana Lo Re, Marco Raffaele, Jan Frohlich, Antoniya Kisheva, Annalisa Crudele, Antonella Mosca, Maria Rita Sartorelli, Clara Balsano, Jan Cerveny, Tommaso Mazza, Anna Alisi, Manlio Vinciguerra – 19 October 2022 – Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in children and adolescents, increasing the risk of its progression toward nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer.

Serum keratin‐18 detects hepatic inflammation and predicts progression in compensated alcohol‐associated liver disease

Katrine Holtz Thorhauge, Maja Thiele, Sönke Detlefsen, Ditlev Nytoft Rasmussen, Stine Johansen, Bjørn Stæhr Madsen, Steen Antonsen, Lars Melholt Rasmussen, Katrine Prier Lindvig, Aleksander Krag – 19 October 2022 – Alcohol‐associated liver fibrosis accumulates over decades, driven by hepatic inflammation and cell death. We investigated the diagnostic accuracy of keratin‐18 degradation, measured using serum M30 and M65 levels, and the ActiTest for hepatic inflammatory activity in patients with compensated alcohol‐associated liver disease (ALD).

Subscribe to